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1. Introduction 
Gliomas are brain tumors with glial cell characteristics, and are composed of a 
heterogeneous mix of cells, which includes glioma stem cells. Gliomas include astrocytomas, 
oligodendrogliomas, ependymoma, and mixed gliomas. Gliomas account for 32% of all 
brain and central nervous system tumors (CNS) and 80% of all malignant brain and CNS 
tumors (CBTRUS, 2010). The WHO grade III anaplastic astrocytomas (AAs) and grade IV 
glioblastoma multiforme (GBMs) are highly invasive tumors and make up approximately 
three-quarters of all gliomas (CBTRUS, 2010). GBM is the most common and malignant form 
of brain tumor. GBMs make up 17% of all primary brain tumors in the United States, with 
an incidence of 3.17 cases per 100,000 persons per year (CBTRUS, 2010). Although both the 
knowledge of glioma biology and the available resources for treatment have greatly 
increased over the past decade, the expected survival of malignant glioma patients remains 
dismal. For AA patients, the current five-year and ten-year survival rates are 27.4% and 
21.3%, respectively (CBTRUS, 2010). GBM patients have a much lower survival. The current 
five-year and ten-year survival rates for GBM patients are 4.5% and 2.7%, respectively 
(CBTRUS, 2010). Clinical treatment for gliomas consists of a combination of surgical 
resection, radiotherapy and chemotherapy. Due to the infiltrative nature of GBMs, complete 
removal of the tumor by surgery is not possible. Following surgery, the conventional 
radiation dosage of up to 60 Gy is given daily in 2 Gy fractions (Buatti et al 2008). The 
commonly used chemotherapy drug, temozolomide (Temodar®), is an alkylating agent that 
is taken orally and readily penetrates the blood-brain barrier (Ostermann et al., 2004). 1,3-
bis(2-chloroethyl)-1-nitrosourea (BCNU) is an older drug that surgeons deposit in the tumor 
bed as dissolvable wafers (Grossman et al., 1992). Both of these drugs alkylate DNA at 
multiple sites, including the O6 position of guanine, which can result in futile cycles of DNA 
repair and, ultimately, cell death (Sarkaria et al., 2008). These alkylating agents can also 
induce senescence (Gunther et al., 2003). Temozolomide is administered as both concomitant 
and adjuvant treatments to radiotherapy. This aggressive treatment increases the two-year 
survival rate for GBM patients from 10.4%, with radiotherapy alone, to 26.5% (Stupp et al., 
2005). Cells that escape radiotherapy- and chemotherapy-induced cell death eventually re-
enter the cell cycle and contribute to local tumor recurrence. Despite advances in 
chemotherapy regimens, the median progression free survival in AA and GBM patients is, 
15.2 months (Chamberlain et al., 2008) and 6.9 months (Stupp et al., 2005), respectively. The 
median overall survival time for GBMs is 14.6 months (Stupp et al., 2005).  
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2. Discovery of neural and glioma stem cells 
The discovery of adult neural stem cells paved the way for the glioma stem cell field. Until 
the mid-20th century, the consensus in the neuroscience field was that adult neural stem cells 
did not exist. The former dogma was that the brain contained mitotic cells only during 
development. It is now known that neurogenesis persists throughout life. In the adult brain, 
neural stem cells are located primarily in the subventricular zone (Altman, 1963) and the 
dentate gyrus (Altman and Das, 1965). In the subventricular zone, adult neural stem cells are 
termed type B cells and the transit-amplifying cells are type C cells (Kriegstein and Alvarez-
Buylla, 2009) (FIG 1a). The type B neural stem cells are mostly quiescent and are derived from 
embryonic and neonatal radial glial cells. Type B cells structurally resemble astroglial cells 
(Doetsch et al., 1997). The adult neural stem cells and transit-amplifying cells are closely 
associated with blood vessels in the subventricular zone (Tavazoie et al., 2008). In the dentate 
gyrus of the hippocampus, the radial astrocytes are neural stem cells of the subgranular zone 
of the dentate gyrus (Seri et al., 2004). These cells are also referred to as type I progenitors in 
the subgranular zone (Fukuda et al., 2003). The subgranular zone is also located next to a 
vascular network, suggesting a niche for adult neural stem cells (Palmer et al., 2000). Adult 
neural stem cells from both the subventricular and subgranular zones express the embryonic 
neural stem cell markers nestin and Sox2, in addition to the astrocytic marker, glial fibrillary 
acidic protein (GFAP) (Doetsch et al., 1999; Seri et al., 2004; Suh et al., 2007). Unlike their 
differentiated progeny, these cells possess the ability to form neurospheres in serum-free 
cultures supplemented with growth factors (Reynolds et al., 1992). Neurospheres are 
heterogeneous aggregates derived from a single cell. These single cells would be plated at low 
densities for neurosphere assays, which were originally used to determine the percentage of 
neural stem cells in a culture or tissue. It is now known that both neural stem cells and transit 
amplifying cells can form neurospheres; however, neural stem cells are believed to have a 
greater, long-term proliferation potential than the transit-amplifying cells, and can therefore 
maintain neurosphere cultures through a large number of serial dissociations (Reynolds and 
Weiss, 1996).  Neural stem cells have been associated with repair after strokes and severe 
injuries, and have been suggested as means for treatment of neurological disorders, such as 
Alzheimer’s Disease (Gage, 2000; Zhongling et al., 2009).  
While neural stem cells are necessary for normal neurological development and activity, 
cells with aberrant neural stem cell characteristics have been attributed to brain tumors. 
Glioma stem cells have many characteristics shared with adult neural stem cells, such as 
self-renewal, neurosphere formation, marker expression, multilineage differentiation, high 
motility, and localization to stem cell microenvironment niches (Sanai et al., 2005). Normal 
neural stem cells and glioma stem cells also share similar undifferentiated gene expression 
profiles, including nestin, EGF receptor, and PTEN. However, the nomenclature ‘stem cell’ 
in gliomas refers to their function and not their origin. It is currently unknown what is the 
cell of origin for glioma stem cells. Glioma stem cells may originate from normal neural 
stem cells that have undergone tumorigenic mutations or from more differentiated transit-
amplifying or terminally differentiated neural cells that have undergone multiple mutations 
that allow the cells to be tumorigenic and revert to stemness properties (FIG 1b). Neural 
stem cells are probably target cells for malignant transformation. When rodent brains were 
exposed to avian sarcoma virus or carcinogens, tumors formed in the subventricular zone, 
where normal neural stem cells are believed to reside (Sanai et al., 2005). In addition, 
expression of Akt and K-ras in progenitor cells led to tumorigenesis (Holland et al., 2000). 
Conversely, several laboratories have demonstrated that genetic alterations can 
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Fig. 1. A comparison of the hierarchies for normal neural stem cells and GBM CSCs. 
(A) NSC can either self-renew or differentiate to type B radial glia-like progenitor cells. They 
can then irreversibly differentiate to oligodendrocytes, astrocytes or neurons. (B) For GBM 
CSCs, the stem-like cells self-renew or differentiate to progenitor cells and then to more 
differentiated GFAP+ cells. Unlike the NSC, the differentiated cells may in some cases 
dedifferentiate. 
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Continuation of Fig. 1. 
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dedifferentiated terminally differentiated astrocytes and induce tumorigenesis.(Bachoo et 
al., 2002; Holland et al., 1998)  Due to the substantial heterogeneity among gliomas, it is 
likely that tumors from different patients originate from different stages of the adult neural 
hierarchy. This is an explanation for the distinct molecular subclasses of gliomas (Phillips et 
al., 2006). Regardless of the cell of origin, there are three properties that are considered 
essential for a cell to be universally accepted as a glioma stem cell (Rich, 2008). First, the cell 
must be capable of self-renewal; second, the cell should possess high proliferative potential; 
and third, the glioma stem cell must be capable of tumor initiation. There are additional 
characteristics used to define, but are not required of, glioma stem cells, because they can 
vary among different glioma grades and individual patients’ tumors. Glioma stem cells may 
make up a rare population of the tumor or glioma culture; however, recent publications find 
that the percent of stem cells in different cancers can vary greatly, depending on tumor type 
and possibly the tumor environment (Eaves, 2008). Many laboratories have used the 
expression of stem cell markers to identify and isolate glioma stem cells, although there is 
no single marker that is consistent for all patients, specific to glioma stem cells, and 
definitely includes all glioma stem cells in a tissue. Finally, similar to neural stem cells, 
glioma stem cells are capable of multilineage differentiation, albeit aberrant, and the ratio of 
the differentiated progeny as well as progeny that express markers from multiple lineages 
can be varied between tumors (FIG 1b and c) (Varghese et al., 2008). However, as it is rare 
for an individual glioma to exhibit the full hierarchy see in normal brain tissue from neural 
stem cell differentiation, it is not expected that each glioma stem cell can differentiate into all 
lineages (Sanai et al., 2005). Therefore, one would expect the differentiation of a glioma stem 
cell to mimic the lineage composition of the parent tumor. 
3. Glioma stem cell cultures 
Traditionally, glioma cells were grown in the presence of serum as adherent cultures (FIG 
2). The serum-grown cultures are tumorigenic, but unlike the invasive phenotype seen in 
patient gliomas, serum cultures commonly yield circumscribed tumors in intracranial 
xenograft models (Radaelli et al., 2009). Gene expression in serum cultures can be drastically 
different from the original tumor (Lee et al., 2006). Like neural stem cells, glioma stem cells 
can be grown in serum-free media with the growth factors EGF and FGF (Galli et al., 2004). 
Neurosphere cultures are currently the most common method used to propagate glioma 
stem cells, but a new in vitro technique to grow glioma stem cells is emerging, which utilizes 
laminin-coated plates with serum-free media. 
3.1 Neurosphere cultures 
The presence of self-renewing glioma stem cells was first demonstrated in 2003. Two 
laboratories demonstrated that glioma tissue cultured in serum-free media supplemented 
with growth factors form non-adherent spheroids with an enhanced glioma stem cell 
population (FIG 2 and 3). The glioma neurosphere cultures maintain genetic profiles similar 
to the original patients’ tumors and form invasive tumors in intracranial xenografts (Ernst et 
al., 2009; Lee et al., 2006; Singh et al., 2004). When plated at clonal density, each neurosphere 
arises from an individual glioma stem cell or transit-amplifying cell. Despite their clonal 
origin, neurospheres are heterogeneous aggregates that consist of glioma stem cells, transit-
amplifying cells, and more differentiated glioma cells. The percentage of neurosphere-
initiating can vary greatly among glioma cultures, and neurosphere formation has been 
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demonstrated to increase when neural stem cells are transformed (Li et al., 2009). The 
majority of cells in a neurosphere are transit-amplifying cells (Ahmed, 2009). When these 
neurosphere cultures are dissociated to single cells, a small percentage of the cells can form 
secondary and tertiary neurospheres for many passages (Chen et al., 2010; Reynolds and 
Weiss, 1996).  Glioma stem cells have a high capacity to proliferate and self-renew and 
robustly form secondary neurospheres.  
When exposed to fetal bovine serum, neurosphere cells differentiate down the lineage of 
the parent tumor (Singh et al., 2003). Therefore, gliomas preferentially differentiate to 
astrocytes, but multilineage differentiation can occasionally be observed with neuronal 
lineages, and some abnormal cells with mixed phenotypes. It should be noted that these 
lineages are based on markers but not function. For example, the crucial test for a neuron 
is an action potential, which is not tested. Also, a significant difference between neural 
stem cell and glioma stem cell cultures is that serum differentiation of normal neural stem 
cells is permanent (Lee et al., 2006), while glioma lines established as serum cultures 
can be converted to neurospheres in serum-free media (Gilbert et al., 2010; Qiang et al., 
2009). 
Neurosphere cultures express known neural stem cell genes, such as Musashi-1, Sox2, and 
Bmi-1 (Hemmati et al., 2003) (FIG 2). Stem cell membrane markers, such as CD133 and 
CD15, are also expressed in neurosphere cultures and are discussed in further detail in 
subsequent sections. Using neurosphere assays to analyze glioma stem cell content can be 
complicated. As mentioned above, both glioma stem cells and transit amplifying cells are 
capable of neurosphere formation. In addition, neurospheres aggregate and fuse with one 
another when the cells are plated at higher densities (Singec et al., 2006). Therefore, the 
number of neurospheres is a measure of the number of both glioma stem cells and transit 
amplifying cells and is accurate only when the cells are plated at low densities. Despite these 
concerns, neurosphere cultures remain a valuable tool in glioma stem cell research.  
3.2 Laminin-coated cultures 
A key aspect of the neurosphere culture system is that the serum-free, defined media 
maintains the glioma stem cell phenotype of the cells. However, in addition to glioma 
stem cells, neurospheres contain more differentiated progeny and regions of cell death. 
This is thought to be caused by the condensed structure of the neurosphere, which 
hinders the diffusion of the growth factors to the innermost cells (Woolard and Fine, 
2009). Differentiation and cell death could be limited if glioma cultures were grown in a 
monolayer in the presence of serum-free, defined medium. This can be achieved by 
culturing glioma samples in the serum-free, defined medium on laminin-coated cell 
culture plates (Pollard et al., 2009). When cultured on laminin-coated plates, cells that 
would normally form neurospheres grow as an adherent culture, which allows all of the 
cells equal access to growth factors. The adherent glioma stem cell lines are less 
heterogeneous than neurosphere cultures, and almost all of the cells express glioma stem 
cell genes, such as Sox2, Nestin, CD133 and CD44 (FIG 2). There is minimal expression of 
differentiation markers. The adherent, laminin cultures are capable of tumor formation 
when as few as 100 cells were intracranially injected into immunocompromised mice, 
demonstrating the high percentage of tumor-initiating glioma stem cells. An additional 
benefit of the laminin glioma stem cell culture system is that all gliomas with good cell 
viability formed long-term cell lines.  
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Fig. 2. Proposed lineages and culture methods for GBM CSCs. The CSCs (red circles) are 
cultured in defined medium to enhance stem cell properties. They express stem cell 
markers, listed below. CSCs are likely heterogeneous and may not express all of these 
markers, and may show additional tumor-to-tumor variation.  CSCs differentiate to transit-
amplifying cells (blue circles). The transit-amplifying cells show decreased expression of 
stem cell markers, and Chen et al (2010) recently suggested that TBR2 and DLX2 are markers 
for these cells. In mature spheres, a few of the transit-amplifying cells differentiate to 
astrocytic cells and, to a lesser degree, neuronal and oligodendrocytic cells (astrocytic cells 
shown as green circles). For cells adhering to laminin-coated substratum, stem cell marker 
expression is enhances, suggesting that the fraction of CSCs is increased. In addition, there 
are very few astrocytic cells. Serum treatment rapidly induces astrocytic differentiation. 
4. Glioma stem cell markers 
Markers are commonly used to identify and isolate different cells types. The most 
commonly used cell surface markers for glioma stem cells are CD133, CD15, and A2B5. 
New, less characterized markers are also being tested for glioma stem cells. When cells are 
isolated from tumors or glioma cultures with these markers, their stem cell characteristics 
can be analyzed based on stem cell gene expression, multilineage differentiation capabilities 
and neurosphere formation; however, tumor formation in xenograft models is the most 
important method to confirm that a marker identifies the glioma stem cell population. 
Despite many successes using cell surface markers such as CD133, it has become 
increasingly clear that individual gliomas are very heterogeneous and in addition, tumors 
vary greatly from patient to patient (Phillips et al., 2006). There is currently no universally 
accepted collection of markers for isolation of a pure population of glioma stem cells 
(Gilbert and Ross, 2009). In addition, to complicate the glioma stem cell field, some of the 
markers used appear to only be relevant when the cells are isolated directly from the tumor 
tissue. The heterogeneity of malignant gliomas may make it difficult to use a single set of 
markers to identify and purify glioma stem cells in every glioma. 
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4.1 CD133 
CD133 (also known as Prominin-1) was first discovered as a cell surface marker for 
hematopoietic stem cells (Miraglia et al., 1997). In the human fetal brain, CD133 is a marker 
for neural stem cells (Uchida et al., 2000). CD133 expression has also been observed in 
intermediate radial glial cells in the early postnatal brain, and in ependymal cells in the 
adult brain (Coskun et al., 2008; Pfenninger et al., 2007). Neurogenic astrocytes in the neural 
stem cell region of the subventricular zone do not express CD133. Despite its inconsistent 
expression in adult neural stem cells, CD133 has been used to isolate populations of cancer 
stem cells from multiple types of brain tumors (Singh et al., 2003; Singh et al., 2004). 
Expression of CD133 in anaplastic astrocytomas and glioblastoma multiforme varies among 
patients and tumor grade, with reports of 0 – 64% (Ogden et al., 2008; Singh et al., 2003; 
Singh et al., 2004; Son et al., 2009). CD133+ cells from gliomas are capable of multilineage 
differentiation and have a high capacity for neurosphere formation. The corresponding 
CD133- cells did not proliferate in neurosphere cultures. Furthermore, CD133+ glioma cells 
express significantly higher levels of neural stem cell genes, such as nestin, Msi-1, maternal 
embryonic leucine zipper kinase (MELK) and CXCR4 (Liu et al., 2006). These data support 
the stem cell genotype of CD133+ glioma stem cells and suggests that similar signaling 
pathways may be involved in normal neural stem cells and brain cancers. The gold standard 
to classify a cell as a glioma stem cell is that it can form a xenograft tumor that is capable of 
serial transplantations in immunodeficient mice. CD133+ glioma cells have an increased 
capacity for tumor initiation after intracranial transplantation into mice (Singh et al., 2004). 
Injection of only 100 CD133+ cells results in tumors capable of serial transplantation, while 
100,000 CD133- injected cells do not form tumors. It is important to note that the laboratories 
that have had the most success studying glioma stem cells based on CD133 expression have 
isolated the cells from primary patient tissue and fresh xenograft samples (Bao et al., 2006a; 
Singh et al., 2004; Wang et al., 2010).  
CD133 knockout mice manifest with a progressive photoreceptor degeneration that leads to 
total vision loss (Zacchigna et al., 2009). It is surprising that with the wide range of 
expression of cells expressing CD133 throughout the body and its link to stem cells that 
there are not more developmental defects. However, the authors suggest that further studies 
to characterize the mice under stressed conditions may uncover other defects in the CD133 -
/- mouse model. An additional explanation is that the family member Prominin-2, which 
may provide redundant functions, is co-expressed in most tissues, excluding the retina 
(Fargeas et al., 2003). Other than its involvement in retinal development, little is known 
about CD133 function. Recent reports demonstrate that its expression may be cell cycle-
dependent (Beier et al., 2007; Jaksch et al., 2008) or regulated by hypoxic environments 
(Griguer et al., 2008). In addition, in the small intestines and the prostate, CD133 marks both 
the transit-amplifying population and the stem cells (Grey et al., 2009; Snippert et al., 2009). 
These data imply that CD133 may only identify a subset of glioma stem cells that are 
actively proliferating, and CD133+ populations may include progenitor cells.  
A rising concern for CD133 as a glioma stem cell marker is that up to 40% of freshly isolated 
glioma tumors do not express CD133 (Son et al., 2009). Tumors negative for CD133 
expression still included cells with stem cell-like properties of self-renewal, multilineage 
differentiation, and xenograft tumor formation (Beier et al., 2007). Differences in CD133 
expression among gliomas may be result from the origin of the tumor-initiating cell (Lottaz 
et al., 2010). Cells isolated from CD133+ tumors express a “proneural” gene signature and 
resemble fetal neural stem cells, while cells from CD133- tumors have “mesenchymal” genes 
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cells expressing A2B5 form tumors regardless of their CD133 status, A2B5 appears to 
identify an additional glioma stem cell population. Ogden et al., state that the A2B5 data do 
not diminish the utility of CD133 as a glioma stem cell marker, but rather demonstrates a 
broader population of cells capable of tumor formation. Contrarily, the very high percentage 
of A2B5+ cells brings up the question of the rarity of the tumor initiating, cancer stem cell in 
some tissues. It will be interesting to see in the future if additional markers can identify a 
purer subset of glioma stem cells from the A2B5+ population, or if like observed in 
melanomas (Quintana et al., 2008), the glioma stem cell population could make up a very 
large percent of the tumor. 
4.3 CD15 
CD15 (also known as SSEA-1 and Lewis-X Antigen) is a carbohydrate adhesion molecule 
associated with glycolipids and glycoproteins. CD15 expression has been shown on neural 
stem cells derived from human embryonic stem cells and embryonic neural stem cells 
(Barraud et al., 2007; Pruszak et al., 2007). In freshly isolated GBMs, distinct populations of 
CD15 varied from 2.4 – 70% (Son et al., 2009). CD15+ cells had increased expression of stem 
cell genes, such as Sox2 and Bmi1, and were capable of self-renewal and multilineage 
differentiation. CD15+ cells also form neurospheres in serum-free, defined medium, while 
CD15- cells had minimal neurosphere formation (Mao et al., 2009). A large percent of 
CD133+ cells co-expressed CD15, but there was also a unique population of CD15+/CD133- 
cells. Additionally, tumors negative for CD133 possessed CD15+ cells (Son et al., 2009). 
CD15+ cells isolated from GBMs were highly tumorigenic, while SSEA-1- cells displayed 
limited tumor formation in mouse intracranial xenografts. Importantly, 23 out of 24 primary 
GBMs analyzed contained a subpopulation of CD15+ cells. Cells expressing CD15 that were 
isolated from CD15+/CD133- neurospheres were capable of forming intracranial tumors in 
mice (Mao et al., 2009). These results together suggest that CD15 is a useful marker for both 
normal neural stem cells and glioma stem cells, and may identify new CD133- glioma stem 
cells. 
4.4 New markers: Podoplanin and Integrin Alpha 6 
There are two new promising cancer stem cell markers. The first, podoplanin, is a mucin-
type transmembrane glycoprotein. It is over expressed in a variety of cancers, including 
squamous cell carcinomas, colorectal carcinomas and brain tumors (Cortez et al., 2010). For 
glioblastomas, podoplanin is expressed both in tumors and primary neurospheres in culture 
(Christensen Neurosurgery 2010). Elevated levels of podoplanin are associated with 
invasiveness, but the mechanism is not known (Cortez et al., 2010; Shen et al., 2010). The 
second new marker, integrin alpha 6, plays an important role in normal neural stem cells 
(Lathia et al., 2010). Integrin alpha 6 binds laminin and plays a role in maintaining the stem 
cells in the subventricular zone. Lathia et al. provided strong evidence that integrin alpha 6-
positive cells have cancer stem cell characteristics. These cells are more proliferative and 
potent for neurosphere and tumor formation. 
5. Glioma stem cell protection mechanisms 
5.1 Immunosuppression 
The capacity to evade tumor surveillance by the immune system may be a key step in the 
development of cancer and may involve cancer stem cells (Jaiswal et al., 2010). The immune 
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responses to GBMs can be potent (Di Tomaso et al., 2010; Lichtor and Glick, 2003). For 
example, dendritic cells loaded with glioma cancer stem cells and then injected 
subcutaneously substantially suppress intracranial tumor growth (Pellegatta et al., 2006). 
Ironically, antigens associated with glioma cancer stem cells may activate the immune 
system, and by an independent mechanism, GBM cells may suppress the immune system. 
GBMs secrete immunosuppressive factors, including TGF-β, VEGF, PGE2, B7-H1, galectin-3 
and CCL-2 (Wei et al., 2010). Conditioned medium from GBMs inhibits T-cell proliferation 
and induces T regulatory cells (Tregs), which can suppress the functions of T-cells, B-cells, 
dendritic cells, monocytes, macrophages and natural killer (NK) cells (Humphries et al., 
2010; Wei et al., 2010). Di Tomaso and colleagues (2010) found that glioma stem cells were 
particularly effective for inhibition of T-cell proliferation. In addition, phagocytic cells can 
play an important role in clearing tumor cells (Jaiswal et al., 2010), and high-grade GBMs 
may include up to 30% microglia cells (Hanisch and Kettenmann, 2007). Rodrigues et al. 
(2010) concluded that GBMs suppress activation of microglial cells, and the GBM-
suppressed microglial cells, in turn, suppress T-cell activity by secreting 
immunosuppressive factors, IL-10 and Fas-ligand. The multiple immunosuppressive 
mechanisms are consistent with our view that interactions with the immune system play a 
major role in the development of GBMs. 
It has been suggested that cancer is a result of malignant cells evading the body’s immune 
system. Glioma stem cells disrupt tumor immunosurveillance and result in both ineffective 
adaptive and innate immune responses. This is another mechanism that glioma stem cells 
help protect the tumor, which results in high rates of tumor recurrence and patient death. 
Theoretically, targeting the glioma stem cell-induced immunosuppression can enhance the 
survival of glioma patients. 
5.2 Chemoresistance and radioresistance 
By several mechanisms, the stem cell character of glioma stem cells may also contribute to 
resistance of tumor cells to therapy (FIG 4). First, normal stem cells can assume a quiescent 
state that is regulated by the stem cell niche. Cells that are not proliferating or stop after 
DNA damage have an enhanced chance of survival. Several groups have proposed that 
cancer stem cells readily assume a quiescent state and later, following DNA repair, 
repopulate the tumor (Mellor et al., 2005; Scopelliti et al., 2009). Our laboratory recently 
demonstrated that even low doses of temozolomide can induce quiescence followed by a 
robust recovery of the culture (Mihaliak et al., 2010). The neurosphere recovery assay 
provides a quantitative cell culture assay to test the efficacy of drug combinations at 
inhibiting repopulation. We demonstrated that temozolomide drastically diminished initial 
neurosphere formation in many glioma cultures; however, these cultures eventually 
recovered and formed a robust number of secondary neurospheres (Mihaliak et al., 2010). 
The ability of temozolomide treated neurospheres to recover and repopulate the culture 
suggests that some cells undergo a transient cell cycle arrest, allowing them to evade cell 
death and eventually resume proliferation. CD133+ cells were more resistant to multiple 
chemotherapeutic agents, including temozolomide, compared to CD133- cells from the same 
primary glioma cultures (Liu et al., 2006). Glioma cells that survived after 1,3-bis(2-
chloroethyl)-1-nitrosourea (BCNU) treatment expressed high levels of CD133+ and retained 
their tumorigenic potential in intracranial mouse xenografts (Kang and Kang, 2007). In 
addition, ionizing radiation enriched the CD133+ population of human glioma cultures  
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Fig. 4. CSCs and cancer therapy. The CSC model helps us to understand why current cancer 
therapies fail and aids development of novel, more effective approaches. (A) It has been 
proposed that CSCs (red circles) are resistant to current cancer therapy, survive even the 
most rigorous therapies that kill the more differentiated cells (blue circles) and allow tumor 
repopulation. (B) One of the most appealing aspects of the CSC model is that therapies 
directed against CSCs might eliminate the cells with long-term self-renewal potential, and 
the more differentiated cells, which lack self-renewal potential, will eventually cease cell 
proliferation and die. (C) In a more recent CSC model (Chen et al and Fig. 1), some 
differentiated cells can revert to CSCs. If this model is correct, then a therapy exclusively 
directed against the CSCs would allow creation of new CSCs and repopulation of the tumor. 
(D) A new approach that takes into account dedifferentiation is to combine CSC directed 
therapy to decrease the number of the most important cells and a nonspecific therapy to 
clear the differentiated cells and, thereby, reduce the chance of dedifferentiation. 
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derived from xenografts and GBM patient samples (Bao et al., 2006a). Based on these data, 
CD133+ populations were more resistant to ionizing radiation in colony formation assays 
compared to the corresponding CD133- populations. On the other hand, it has been shown 
that number of CD133+ glioma cells can decrease or show no significant change after 
chemotherapy treatment (Beier et al., 2008; Mihaliak et al., 2010). There may be several 
explanations for these inconsistent results. First, these  differences could support the issue 
that CD133 is not a universal stem cell marker for all gliomas. Second, they could be due to 
different  sources of the glioma stem cells, for example neurosphere cultures, versus 
xenografts, versus fresh patient tissue. Finally, the disparate results may be on account of 
the time points that the data are analyzed after treatments and the concentrations of the 
drug treatments. Mihaliak et al. (2010) demonstrated that the chemotherapy treatments 
induced a cell cycle arrest in the neurosphere initiating cells at clinically relevant doses, but 
required higher concentrations to induce cell death in the bulk of the cells. The drug 
concentrations to achieve this cell cycle arrest varied both by cell line and by the 
chemotherapy drug used. Therefore, depending on the time point that the culture is 
analyzed, the ratios of glioma stem cells to the total bulk cells can greatly vary. 
Another feature that normal stem cells and glioma stem cells share is expression of drug 
efflux pumps. Adenosine triphosphate-binding cassette (ABC) pumps, ABCG2 and P-
glycoprotein are expressed on glioma stem cells and are responsible for efflux of the 
fluorescent Hoechst 33342 dye, leading to the side population, which is enriched in glioma 
stem cells (Lu and Shervington, 2008). However, in a model system, ABCG2-positive and -
negative cells showed no difference in tumor formation in mice (Patrawala et al., 2005). The 
ABC transporters are often proposed to enhance survival of glioma stem cells by efflux of 
chemotherapy drugs, but temozolomide is not a substrate for ABCG2, and expression of 
ABCG2 did not provide resistance to temozolomide treatment (Bleau et al., 2009). 
Glioma stem cells express a variety of proteins that promote survival following cancer 
treatment. The major drug resistance protein, MGMT, and anti-apoptotic genes such as 
FLIP, BCL-2, BCL-XL, cIAP1 and survivin were upregulated in CD133+ glioma cells (Ghods 
et al., 2007; Liu et al., 2006). Ionizing radiation resulted in a greater activation of DNA 
checkpoint responses in CD133+ cells by phosphorylation of Rad15, ATM, Chk1 and Chk2 
than in the autologous CD133- cells (Bao et al., 2006a). This indicates that CD133+ glioma 
stem cells resistance to radiotherapy is partially due to enhanced DNA repair. As a result, 
pathways related to glioma stem cell functions and resistance to therapy will be promising 
targets for novel therapies. 
6. Therapeutic targets 
Current glioma treatments target the bulk of the tumor, but are insufficient (FIG 4). Since 
tumor recurrence is attributed to glioma stem cell therapy resistance, treatments that 
directly target glioma stem cells could yield long-term cures. Many have hypothesized that 
once the glioma stem cells have been eliminated, the bulk tumor would not be able to 
sustain itself and would disseminate; however, in gliomas, it has been hypothesized that 
some differentiated tumor cells have the ability to revert to stem cell-like cells (FIG 2 and 4) 
(Chen et al., 2010; Gupta et al., 2009). The most affective treatments would consist of 
radiation and chemotherapy against the bulk tumor combined with direct-targeted against 
the glioma stem cell population. Signaling pathways associated with either mechanisms of 
resistance or pathways required for the function of glioma stem cells could be targeted to 
enhance therapy.  
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6.1 Notch pathway 
The Notch signaling pathway is an important regulator in normal development, adult stem 
cell maintenance, and tumorigenesis in multiple organs, including the brain (Koch and 
Radtke, 2007). Notch signaling is a promising pathway to target glioma cells, since the 
Notch receptors, their ligands, and downstream targets are commonly over-expressed in 
glioma tissue and cell lines (Fischer and Gessler, 2007; Kanamori et al., 2007; Shih and 
Holland, 2006). The Notch gene mutation was first discovered in flies with ‘notched’ wings 
(Radtke and Raj, 2003). There are four mammalian Notch receptors (Notch1 through 4) and 
five membrane-associated ligands in the Delta and Jagged families. Activation of the Notch 
pathway through cell-cell interactions initiates a signaling cascade (Pannuti et al., 2010). 
When a ligand binds to a Notch receptor, the metalloprotease ADAM protein cleaves the 
extracellular domain of Notch, which initiates intracellular cleavage by the gamma secretase 
complex (Stockhausen et al., 2010). The gamma-secretase cleavage releases the Notch 
intracellular domain (NICD), which facilitates its translocation into the nucleus (Miele, 
2006). The NICD forms a complex with CSL (CBF1/Suppressor of Hairless/Lag1) and 
drives transcription of downstream targets, including members of the Hairy enhancer of 
split (Hes) and Hes-related repressor protein (HERP/Hey) families (Iso et al., 2003), cyclin D 
(Ronchini and Capobianco, 2001), and c-myc (Sharma et al., 2006), and p21 (Guo et al., 2009). 
Notch signaling is a promising target for directed therapy since it can be blocked at multiple 
stages of the pathway (Rizzo et al., 2008). The most common approach to block the Notch 
pathway in basic research, and in Phase I and Phase II clinical trials, is via small molecule 
inhibitors of gamma-secretase (Miele, 2006). Administration of gamma-secretase inhibitors 
blocks the cleavage of the Notch receptor, and the intracellular domain remains bound to 
the cellular membrane, halting the Notch signaling cascade. Treatment with gamma-
secretase inhibitors can lead to gastrointestinal tract cytotoxicity (Barten et al., 2006); 
however, intermittent treatment schedules can to diminish these side effects (Rizzo et al., 
2008).  
Inhibiting the Notch signaling pathway can target the glioma stem cell population. Notch 
signaling directly activates transcription of the stem cell marker, nestin (Shih and Holland, 
2006). Expression of nestin in a murine K-ras glioma model was demonstrated to correlate 
specifically with Notch activation. Likewise, knockdown of Notch by shRNAs or γ-secretase 
inhibitors decreased the expression of stem cell markers nestin and CD133 and decreased 
neurosphere formation (Jeon et al., 2008). Inhibiting the Notch pathway through gamma-
secretase inhibitors or shRNAs against Notch1, both led to suppression of cell growth and 
increased differentiation (Kanamori et al., 2007). In glioma cultures, GSI treatment 
suppressed cell growth and decreased neurosphere formation and tumor growth of CD133+ 
cells (Fan et al., 2010). Correspondingly, increased Notch signaling enhanced glioma cell 
survival (Purow et al., 2005). Gamma-secretase inhibitors were also shown to sensitize 
glioma neurosphere cultures to radiation, thereby, increasing the efficacy of radiotherapy 
(Wang et al., 2010). The combination of temozolomide chemotherapy with gamma-secretase 
inhibitor treatment also decreased neurosphere formation and inhibited neurosphere 
recovery (Gilbert et al., 2010). Ex vivo treatment of glioma xenografts with temozolomide 
and gamma-secretase inhibitors extended tumor latency and survival, and in vivo 
temozolomide and gamma-secretase inhibitor treatment blocked tumor progression in 50% 
of mice with pre-existing tumors. These results suggest that an active Notch pathway 
maintains the glioma stem cell population and provides protection from chemotherapy and 
radiation treatments. Therefore, therapies targeting Notch receptors, ligands and 
downstream targets may enhance current glioma treatments. 
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6.2 Hedgehog pathway 
The Hedgehog gene was first discovered in flies due to a mutation in the gene that caused 
Drosophila larvae to possess hedgehog-like spines (Mohler, 1988). The Hedgehog pathway 
is vital for normal brain development and neural stem cell survival (Ahn and Joyner, 2005; 
Wechsler-Reya and Scott, 1999). There are three mammalian Hedgehog homologues, the 
most studied being Sonic Hedgehog (Marti and Bovolenta, 2002). Sonic Hedgehog is the 
ligand that activates the pathway, and when it is not present, the Patched receptor inhibits 
the Smoothed membrane-bound protein. When the ligand binds to Patched, Smoothened is 
activated, which in turn activates the downstream targets of the Gli transcription factors 
(Gli1 through 3), which were first discovered in human glioma (Kinzler et al., 1987). Glioma 
cell lines and primary glioma tissues commonly express Patched, Sonic Hedgehog and Gli 
(Clement et al., 2007; Dahmane et al., 2001). The Hedgehog pathway can be blocked with 
steroidal alkaloid, Smoothened inhibitor, cyclopamine (Chen et al., 2002). Cyclopamine is a 
naturally occurring compound that was discovered in a fascinating manner. The compound 
was named after a group of lambs that were born with one eye in the center of their 
forehead, imitating a Cyclops (Binns et al., 1964). The parental sheep had grazed on wild 
corn lilies that produced the cyclopamine, leading to incomplete developmental growth, 
which was later attributed to the inhibition of the Hedgehog pathway (Cooper et al., 1998).   
The Hedgehog pathway plays an important role in glioma tumorigenesis. Treatment of 
neurosphere cultures with cyclopamine, inhibited sphere formation, and enhanced radiation 
treatment (Bar et al., 2007) and temozolomide chemotherapy (Clement et al., 2007). 
Cyclopamine treatment also depleted the number of nestin+ cells, CD133+ cells, and the 
Hoechst 33342 side population, suggesting that inhibition of the Hedgehog pathway 
decreases the glioma stem cells (Bar et al., 2007). In vivo cyclopamine treatment reduced 
tumor volume intracranial neurosphere xenografts (Clement et al., 2007). Active Hedgehog 
signaling in glioma cultures increased survival after chemotherapy and Gli1 expression in 
patient tissues is associated with glioma recurrence after chemotherapy (Cui et al., 2010). 
Treatment with cyclopamine to block the Hedgehog pathway increased the cytotoxicity in 
chemotherapy treated cultures. These data suggest that inhibiting the Hedgehog pathway 
enhances the sensitivity to current GBM radiation and chemotherapy treatments by 
targeting the glioma stem cell population.  
6.3 VEGF, Angiogenesis, and Bevacizumab 
Aberrant, inordinate angiogenesis is a hallmark of malignant gliomas. This abnormal 
angiogenesis supports tumor growth and has been considered a target for glioma therapy. 
Glioma stem cells have been associated with a vascular stem cell niche. Nestin+ and CD133+ 
brain tumor cells were consistently located in the proximity of the tumor’s vascular system 
(Calabrese et al., 2007). It has been demonstrated that xenografts from CD133+ glioma cells 
form highly vascular tumors compared to xenografts from CD133- cells (Bao et al., 2006b). In 
addition, secretion of vascular endothelial growth factor (VEGF) from CD133+ cells was 
consistently upregulated. The VEGF family and the tyrosine kinase VEGF receptors are 
important in glioma angiogenesis. When VEGF binds to the receptor, the MAP kinase 
pathway, the Raf-MEK-Erk pathway, and the PI3K-Akt pathway are activated (Korpanty et 
al., 2010). The VEGF pathway can be blocked with the FDA-approved bevacizumab 
(Avastin™), a neutralizing monoclonal antibody against free VEGF. Bevacizumab in vivo 
treatment inhibited the growth of subcutaneous and intracranial CD133+ glioma xenografts 
(Bao et al., 2006b). Anti-angiogenesis treatments have been demonstrated to decrease glioma 
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growth. The vascular niche may regulate glioma stem cell proliferation and provide a 
protective shield for glioma stem cells against treatment. Therefore, therapies targeting the 
fundamental angiogenic factors could simultaneously be a treatment against glioma stem 
cells. Early results from clinical trials with bevacizumab have proved hopeful (Desjardins et 
al., 2008; Friedman et al., 2009; Kreisl et al., 2009). Although there have been only minimal, 
well-tolerated side effects (Rahman et al., 2010), the gliomas that recur after bevacizumab 
treatment are diffuse tumors that are unusually distant from  the primary glioma (Zuniga et 
al., 2009). 
Current glioma therapies may fail to cure patients because glioma stem cells possess 
mechanisms to evade treatments and enhance survival. The remaining cells promote tumor 
regrowth. To circumvent the many protective features of glioma stem cells, such as 
chemoresistance, radioresistance, and immunosuppression, therapies for glioma stem cells 
must target the vital pathways for glioma stem cell function and their vascular niche. 
Combining drugs that target glioma stem cells with surgery, current chemotherapies, and 
radiation will enhance the overall survival for glioma treatment and decrease tumor 
recurrence.  
7. Summary and future directions of the glioma stem cell field 
In our view, the cancer stem cell model has had a positive effect on cancer research, leading 
to a close examination of tumor cell heterogeneity brought about by differentiation, as well 
as other causes (Shackleton et al., 2009). However, the model has also led to a series of new 
questions and controversies. First, is this model applicable to all gliomas? Ogden et al. (2008) 
found that CD133 only identifies cancer stem cells in a small subset of GBMs (1/6 tumors). 
In addition, there are CD133- GBMs that are still aggressive tumors (Beier et al., 2007). If 
CD133 does not select for cancer stem cells in every glioma, is there a better, more universal 
marker available? As noted in this review, other markers are being tested, but right now 
there is no agreement in the field. Second, perhaps, the markers are not working because the 
cancer stem cell model is too simple. Chen et al. (2010) proposed that there is no single 
marker signature for the cancer stem cell. Instead, they proposed that there are at least three 
cell types with varying degrees of stemness. An intriguing aspect of this model is the 
hierarchy. In most models, the cancer stem cells irreversibly differentiate to cells with less 
potential for self-renewal and tumor formation. In some cases, the more differentiated cells 
may be able to dedifferentiate back to a stem-like cells (Chen et al., 2010; Gupta et al., 2009). 
Third, what is the best source of cells for glioma stem cell studies, and what is the best 
method to culture these cells? Some of the most thorough studies utilize cells shortly after 
removal of tumors from patients or immunodeficient mice and not cells maintained in 
culture for many passages (Bao et al., 2006a; Singh et al., 2004; Wang et al., 2010). To enhance 
stem cell properties, glioma cells are commonly grown as neurospheres in defined medium. 
A newer method is to grow adherent cells on laminin-coated plastic (Pollard et al., 2009), 
and there are critics and advocates for this method (Reynolds and Vescovi, 2009; Woolard 
and Fine, 2009). Fourth, the most important question for the clinic is whether the glioma 
stem cells are the cells in the tumor that are most resistant to therapy and hence, lead to 
repopulation of the tumor? The disagreements on this point may relate to the preceding 
questions and inconsistencies about glioma stem cell markers and methods to culture these 
cells. Until we agree on what is a glioma stem cell and how to prepare them, disagreements 
between different groups and studies will continue. Given this complexity, what is the best 
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strategy for cancer therapy? Advocates for the cancer stem cell model suggested that 
therapy be directed against glioma stem cells, and the remainder of the tumor cells will 
eventually wither away (Cheng et al., 2010). However, since it has been proposed that the 
differentiated cells can dedifferentiate into stem cell-like cancer cells (Chen et al., 2010; 
Gupta et al., 2009), only targeting the glioma stem cells could lead to tumor recurrence. This 
suggests that to have successful long-term cures of gliomas, combined therapy targeting 
both the bulk of the tumor and the glioma stem cells will be necessary (Cheng et al., 2010). 
Promising research has recently taken this novel approach combining a directed therapy 
against the Notch pathway either with chemotherapy (Gilbert et al., 2010) or radiotherapy 
(Wang et al., 2010). These studies demonstrate the proof-of-principle for the enhancement of 
current therapies with new cancer stem cell directed drugs. The glioma stem cell field is 
continuously growing and it will be exciting to see these translational studies tested in the 
clinical setting.  
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